Gallegos-Vargas JA, López-Chavira A, Floriano-Sánchez E, Rivera-Martínez CG, Ronquillo-Sánchez D, Prestegui-Martel B, Sánchez-Roldán J, Mellnyk A

Language: Spanish
References: 18
Page: 140-157
PDF size: 469.20 Kb.

ABSTRACT

Background: Thyroid tumor pathology is common, with a worldwide prevalence of nodules of 5% in women and 1% in males, 5 to 15% are malignant; is the most common cause of neck surgery at the Central Military Hospital. Cytochrome P450 (CYP) superfamily of enzymes is important in the metabolism of drugs and toxic, presumably active carcinogens. The CYP 1A1 induced by aromatic hydrocarbons has been associated with cancer; studies in thyroid nodules, benign tumor pathology and cancer have not had any definite conclusions.
Objective: To verify if the expression of CYP1A1 gene is over-regulated in malignant thyroid disease regarding benign.
Material and method: An observational, cross-sectional, descriptive and analytical study in which 64 tissue samples were collected, 32 of malignant disease, 32 of benign disease; RNA (Trizol) was extracted and its integrity was verified; RT-PCR was performed for gene expression of CYP 1A1, statistical was applied.
Results: RNA was extracted from 64 samples, RT-PCR was performed, with n=59 final; in statistical analysis p=0.3048 was obtained, although not statistically significant, an over-expression of CYP 1A1 relative in malignant versus benign (factor=1.968) was confirmed, confirming our hypothesis.
Conclusions: We hypothesize an over-expression of CYP 1A1 in thyroid pathology, this was verified, gene expression is increased relative to the endogenous gene GAPDH, both malignancy and benign; even without a significant difference between these, there is a numeric over-expression on CYP 1A1 in malignancy. Much more research is needed in genomic tumor disease of head and neck.

REFERENCES

1. American Thyroid Association (ATA) Guidelines taskforce on thyroid nodules and differentiated thyroid cancer, Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.

2. Hurtado-López L, Basurto-Kuba E, Montes de Oca-Durán ER y col. Prevalencia de nódulo tiroideo en el valle de México. Cir Cir 2011;79:114-117.

3. Gharib H, Papini E, Paschke R. Thyroid nodules: a review of current guidelines, practices, and prospects. Eur J Endocrinol 2008;159:493-505.

4. Rivera M C, López-Chavira A y col. Manejo quirúrgico de los tumores tiroideos en el Hospital Central Militar. Rev Sanid Milit Mex 2007;61: 91-96.

5. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-511.

6. Donato, MT. ¿Qué es el citocromo P-450 y cómo funciona? Anales de la Real Academia Nacional de Farmacia 2004;32-43.

7. Bandrés M, Arribas A. Aspectos Fundamentales del Citocromo. Colección Docencia Universitaria, serie Ciencias Biomédicas. Madrid: 2011.

8. Dees EC, Watkins PB. Role of cytochrome P450 phenotyping in cancer treatment. J Clin Oncol 2005;23:1053-1055.

9. Khlifi R, Messaoud O, Rebai A, et al. Polymorphisms in the human cytochrome P450 and arylamine N-acetyltransferase: susceptibility to head and neck cancers. Biomed Res Int 2013;2013:582768.

10. Database By National Human Genome Research Institute (NHGRI) http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:2595 HUGO Gene Nomenclatura.

11. Shukla RK, Tilak AR, C Kumar C, et al. Associations of CYP1A1, GSTM1 and GSTT1 polymorphisms with lung cancer susceptibility in a Northern Indian Population. Asian Pac J Cancer Prev 2013;14:3345-3349.

12. Beresford AP. CYP1A1: friend or foe? Drug Metab Rev 1993;25:503-517.

13. Reis AA, Silva DM, Curado MP, da Cruz AD. Involvement of CYP1A1, GST, 72TP53 polymorphisms in the pathogenesis of thyroid nodules. Genet Mol Res. 2010;9:2222-2229.

14. Kochetova OV, Gaynullina MK, Viktorova TV. DIO2, TPO, CYP1A1 and CYP1A2 gene polymorphism in women with thyroid disease. Gig Sanit 2014;3:52-56.

15. Irmiakova AR, Kochetova OV, Gaĭnullina MK, et al. Association of polymorph variants of CYP1A2 and CYP1A1 genes with reproductive and thyroid diseases in female workers of petrochemical industry. Med Tr Prom Ekol 2012;5:41-48.

16. Siraj AK, Ibrahim M, Al-Rasheed M, et al. Polymorphisms of selected xenobiotic genes contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. BMC Med Genet 2008;9:61.

17. Guilhen AC1, Bufalo NE, Morari EC et al. Role of the Nacetyltransferase 2 detoxification system in thyroid cancer susceptibility. Clin Cancer Res 2009;15:406-412.

18. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:45.